MC
MRNA icon

Merck & Co’s Moderna MRNA Stock Holding History

Merck & Co’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$162M Hold
2,308,190
– – 30.71% 2
2026
Q1 		$117M Hold
2,308,190
– – 33.56% 1
2025
Q4 		$68.1M Hold
2,308,190
– – 24.64% 2
2025
Q3 		$59.6M Hold
2,308,190
– – 26.15% 2
2025
Q2 		$63.7M Hold
2,308,190
– – 29.54% 2
2025
Q1 		$65.4M Hold
2,308,190
– – 39.83% 1
2024
Q4 		$96M Buy
+2,308,190
New +$110M 37.19% 1

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Merck & Co's MRNA Position: Q2 2026 in Review

Merck & Co held its Moderna (MRNA) position steady in Q2 2026 at 2,308,190 shares worth $162M. The position accounts for 30.71% of the portfolio, ranked #2.

Merck & Co first reported a position in MRNA in Q4 2024 and has held it in 7 quarters since. 783 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Merck & Co held 2,308,190 shares of Moderna worth $162M as of Q2 2026.
  • Merck & Co left its Moderna share count unchanged in Q2 2026.
  • Moderna made up 30.71% of Merck & Co's portfolio in Q2 2026, its #2 holding.
  • Merck & Co first reported a position in Moderna in Q4 2024 and has held it in 7 quarters since.
  • 783 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Merck & Co's 13F filing for Q2 2026, filed 7 Aug 2026.